The IPO market has faced significant turmoil over the past few years, with many companies postponing or canceling their public offering plans due to weak market conditions. However, recent developments indicate a promising shift. Companies like Zenas Biopharma and Biren Technology are making
Sanofi is gearing up to address the rising demand for its respiratory syncytial virus (RSV) antibody drug, Beyfortus, by leveraging a recently approved manufacturing line. The company's proactive measures aim to ensure that there is no repeat of last year's shortages, which created significant
The world of cancer treatment is ever-evolving, and recent developments have brought a glimmer of hope for those battling non-small cell lung cancer (NSCLC). iTeos Therapeutics has unveiled promising results from a mid-stage clinical trial examining the efficacy of combining their drug,
Sleep disorders are a growing public health concern, impacting millions of individuals worldwide. Addressing these disorders effectively has long been a challenge for pharmaceutical companies. Enter Centessa Pharmaceuticals, a London-based biotechnology company that has made headlines with its
The biopharmaceutical industry has been growing steadily, driven by the development of new modalities and biomanufacturing technologies. Traditional bioprocessing methods, while effective, are facing significant challenges as the complexity and diversity of biopharma pipelines increase. This has
In a determined effort to adhere to Nasdaq listing requirements and secure its position in a competitive market, Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, has executed a 1-for-25 reverse stock split. Effective August 19, 2024, this strategic maneuver aims to elevate the
BlueRock Therapeutics, a cell therapy company under Bayer, has recently announced FDA clearance for its Investigational New Drug (IND) application for OpCT-001. This investigational induced pluripotent stem cell (iPSC)-derived therapy aims to treat primary photoreceptor diseases, which are a
NImmune Biopharma has recently announced a strategic partnership with BioTherapeutics aimed at accelerating the development of precision medicines for inflammation and immunology. The collaboration is designed to bolster NImmune’s capabilities by integrating BioTherapeutics’ extensive preclinical
Amid significant strategic shifts and infrastructural investments, KBI Biopharma has decided to discontinue mammalian drug substance manufacturing at its Geneva, Switzerland facility. This move comes following a period of substantial upgrades and expansion, signaling a concerted effort to
In the evolving landscape of cancer treatment, the advent of immunotherapies Keytruda and Opdivo has marked a groundbreaking shift. Over the last decade, these drugs, known as PD1 inhibitors, have revolutionized oncology, offering new hope and significantly altering patient outcomes. Their story is
ITCurated uses cookies to personalize your experience on our website. By continuing to use this site, you agree to our Cookie Policy